Jubilant Pharmova Roorkee facility placed under USFDA import alert
The products that get impacted due to the import alert contributed to less than 3% of FY21 total revenues for the Company.
Noida: Jubilant Pharmova Limited (JPM), has recently announced that U.S. Food and Drug Administration (USFDA) has issued import alert for Roorkee dosage formulations facility in the agency's recent inspection.
The inspection of the facility was conducted in March 2021, the company said in a filing
Earlier, the Roorkee facility received an OAI in December 2018 and then a Warning Letter in March 2019.
The Company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
The agency has exempted Meclizine tablets, Olanzapine orally disintegrating tablets, Risperidone orally disintegrating tablets, Spironolactone tablets, and Valsartan tablets from the import alert subject to the Company meeting a few conditions.
The products that get impacted due to the import alert contributed to less than 3% of FY21 total revenues for the Company.
Read also: Ocugen, Jubilant HollisterStier partner for manufacturing Covaxin for US
